Kingswood Wealth Advisors LLC Sells 313 Shares of DexCom, Inc. (NASDAQ:DXCM)

Kingswood Wealth Advisors LLC lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 6.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,417 shares of the medical device company’s stock after selling 313 shares during the period. Kingswood Wealth Advisors LLC’s holdings in DexCom were worth $548,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Centaurus Financial Inc. increased its position in DexCom by 5.5% in the first quarter. Centaurus Financial Inc. now owns 1,236 shares of the medical device company’s stock worth $632,000 after buying an additional 64 shares during the last quarter. Stableford Capital II LLC raised its holdings in DexCom by 2.1% during the 4th quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock valued at $563,000 after acquiring an additional 88 shares during the period. Fortis Capital Advisors LLC lifted its position in shares of DexCom by 5.5% during the second quarter. Fortis Capital Advisors LLC now owns 1,744 shares of the medical device company’s stock worth $224,000 after acquiring an additional 91 shares in the last quarter. Ascent Group LLC boosted its holdings in shares of DexCom by 2.1% in the third quarter. Ascent Group LLC now owns 4,778 shares of the medical device company’s stock worth $577,000 after acquiring an additional 98 shares during the period. Finally, Jaffetilchin Investment Partners LLC grew its position in shares of DexCom by 7.7% in the first quarter. Jaffetilchin Investment Partners LLC now owns 1,412 shares of the medical device company’s stock valued at $440,000 after purchasing an additional 101 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of a number of recent analyst reports. Raymond James lifted their target price on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Piper Sandler lifted their price objective on DexCom from $135.00 to $150.00 and gave the company an “overweight” rating in a research note on Tuesday, December 19th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Wells Fargo & Company lifted their price target on DexCom from $110.00 to $136.00 and gave the company an “overweight” rating in a research report on Wednesday, December 13th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average price target of $136.67.

Insider Buying and Selling

In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the transaction, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Sadie Stern sold 2,902 shares of DexCom stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total value of $358,774.26. Following the completion of the sale, the executive vice president now owns 79,051 shares in the company, valued at $9,773,075.13. The disclosure for this sale can be found here. Insiders have sold a total of 183,635 shares of company stock valued at $24,020,621 over the last three months. 0.41% of the stock is owned by company insiders.

DexCom Stock Performance

DexCom stock opened at $139.48 on Thursday. The company has a market capitalization of $53.77 billion, a PE ratio of 106.47, a P/E/G ratio of 2.41 and a beta of 1.18. The firm has a fifty day simple moving average of $125.31 and a two-hundred day simple moving average of $111.84. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the company earned $0.34 EPS. DexCom’s revenue for the quarter was up 26.9% compared to the same quarter last year. Research analysts expect that DexCom, Inc. will post 1.76 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.